SEC Form 4 reporting owner

Nagendran Sukumar

Nagendran Sukumar has filed 15 Form 4 transactions reported between November 28, 2025 and July 10, 2026, as President and Head of R&D of Taysha Gene Therapies, Inc. and a reporting owner of Solid Biosciences Inc..

Name as filed: Nagendran Sukumar

Open-market buys, 24 mo

None

reported

Open-market sales, 24 mo

$4.2M

6 lines

Companies

with Form 4 filings

Latest transaction

Jul 10, 2026

transaction date

Roles and reported holdings

TSHATaysha Gene Therapies, Inc.
Nov 28, 2025 – Jul 10, 2026
President and Head of R&D
Held directly936,410 sh as of Jul 10, 2026 · Form 4
24 months: $4.2M sold
SLDBSolid Biosciences Inc.
Jun 10, 2026
Reporting owner
No common-stock holding reported on a purchase, sale, gift or withholding line.

Transaction history

All 15 reported transactions, newest first. Every row links to the Form 4 on SEC EDGAR.

Date	Company	Type	Shares	Price	Value	Owned after	Filing
Jul 10, 2026	TSHAPresident and Head of R&D	Open-market saleCode S · direct	200,000	$6.24	$1.2M@ $6.24	936,410	Form 4
Jun 10, 2026	SLDB	Grant or awardCode A · direct	77,500	—	—	77,500	Form 4
Apr 10, 2026	TSHAPresident and Head of R&D	Open-market saleCode S · direct	200,000	$4.46	$892K@ $4.46	1,136,410	Form 4
Apr 10, 2026	TSHAPresident and Head of R&D	Option exerciseCode M · direct	19,021	$1.71	$33K@ $1.71	1,336,410	Form 4
Jan 26, 2026	TSHAPresident and Head of R&D	Open-market saleCode S · direct	26,918	$4.61	$124K@ $4.61	1,317,389	Form 4
Jan 23, 2026	TSHAPresident and Head of R&D	Open-market saleCode S · direct	89,132	$4.75	$423K@ $4.75	1,344,307	Form 4
Jan 12, 2026	TSHAPresident and Head of R&D	Grant or awardCode A · direct	274,000	—	—	274,000	Form 4
Jan 12, 2026	TSHAPresident and Head of R&D	Grant or awardCode A · direct	427,000	—	—	1,433,439	Form 4
Jan 12, 2026	TSHAPresident and Head of R&D	Open-market saleCode S · direct	200,000	$4.71	$942K@ $4.71	1,006,439	Form 4
Jan 12, 2026	TSHAPresident and Head of R&D	Option exerciseCode M · direct	88,676	$1.71	$152K@ $1.71	1,206,439	Form 4
Jan 12, 2026	TSHAPresident and Head of R&D	Option exerciseCode M · direct	111,324	$0.6989	$78K@ $0.6989	1,117,763	Form 4
Dec 1, 2025	TSHAPresident and Head of R&D	Option exerciseCode M · direct	260,047	$1.71	$445K@ $1.71	1,266,486	Form 4
Nov 28, 2025	TSHAPresident and Head of R&D	Open-market saleCode S · direct	110,125	$4.75	$523K@ $4.75	1,006,439	Form 4
Nov 28, 2025	TSHAPresident and Head of R&D	Option exerciseCode M · direct	39,953	$1.71	$68K@ $1.71	1,116,564	Form 4
Nov 28, 2025	TSHAPresident and Head of R&D	Option exerciseCode M · direct	70,172	$0.6989	$49K@ $0.6989	1,076,611	Form 4

How this page is built

Every row comes from a Form 4 filed with the SEC, which officers, directors and holders of more than 10% of a company’s stock must file within two business days of a trade. Transactions are grouped by the reporting owner’s name as filed (spacing, capitals and punctuation ignored); two different people filing under an identical name would appear together, and one person filing under two spellings appears on two pages.

Open-market totals count code P purchases and code S sales over the last 24 months. The same trade reported on more than one filing is counted once; when another owner (for example a fund and its general partner) reports the identical trade, they are listed beside it. Holdings are the shares owned after the latest purchase, sale, gift or tax-withholding line, shown separately for direct and indirect ownership; an indirect figure is one holding line, not a total across every trust or entity.

This page describes what was filed with the SEC; it is not investment advice or a recommendation to buy or sell any security.